SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

30 Jan 2026 Evaluate
The turnover soared 74.47% to Rs. 28.09 millions for the December 2025 quarter as compared to Rs. 16.10 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2025 is Rs. -134.71 millions as compared to Net Loss of Rs. -132.73 millions of corresponding quarter ended December 2024 Operating profit Margin for the quarter ended December 2025 further decreased to -121.25% as compared to -117.31% of corresponding quarter ended December 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 28.09 16.10 74.47 55.95 51.89 7.82 66.56 116.93 -43.08
Other Income 27.66 15.69 76.29 71.33 95.35 -25.19 107.26 211.30 -49.24
PBIDT -121.25 -117.31 3.36 -396.63 -274.89 44.29 -412.11 -98.07 320.22
Interest 0.00 0.08 0.00 0.00 0.47 0.00 0.47 1.58 -70.25
PBDT -121.25 -117.39 3.29 -396.63 -275.36 44.04 -412.58 -25.08 1545.06
Depreciation 13.46 15.34 -12.26 40.31 44.75 -9.92 58.22 65.02 -10.46
PBT -134.71 -132.73 1.49 -436.94 -320.11 36.50 -470.80 -90.10 422.53
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.02 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -134.71 -132.73 1.49 -436.94 -320.11 36.50 -470.80 -80.08 487.91
Equity 227.47 218.07 4.31 227.47 218.07 4.31 218.07 218.07 0.00
PBIDTM(%) -431.65 -728.63 -40.76 -708.90 -529.76 33.82 -619.16 -83.87 638.23

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×